Don't miss

Replay


LATEST SHOWS

MEDIAWATCH

Trump: Fake News And Unnamed Sources

Read more

THE WORLD THIS WEEK

Trump Administration, Trukey Crackdown, French Presidential Race (part 1)

Read more

THE WORLD THIS WEEK

Trump Administration, Trukey Crackdown, French Presidential Race (part 2)

Read more

FRANCE IN FOCUS

Aux Champs-Elysées: The story behind France's most famous avenue

Read more

#TECH 24

Foosball gets its own social network

Read more

YOU ARE HERE

Inlays and veneers: The art of French cabinetmaking

Read more

PEOPLE & PROFIT

How should companies respond to a Trump Twitter attack?

Read more

#THE 51%

Trump abortion funding ban: Europe tries to fill the breach

Read more

REPORTERS

Video: India’s Kuki people, possible descendants of one of Israel's lost tribes

Read more

Researchers zero in on Alzheimer's plaque origin

Latest update : 2008-04-09

Researchers have found a key ingredient, produced by a brain cell activity, for the formation of Alzheimer's plaques.

Researchers have found that a key ingredient for the formation of Alzheimer's plaques is produced by a brain cell activity, according to a study that helps understand the disease's origin.

The ability of brain cells to absorb substances from their surface, a process called endocytosis, is essential to producing amyloid beta, a protein fragment that clusters together to form Alzheimer's plaques, said the study released Wednesday.

The researchers found that by giving a drug that blocks endocytosis to a mouse with Alzheimer's disease, levels of amyloid beta sank by 70 percent, according to the study published in the journal Neuron.

But using the drug to treat Alzheimer's is not an option because brain cells need to be able to take in substances from the surface, said the neuroscientists at Washington University School of Medicine in St. Louis.

"Blocking endocytosis isn't a viable option for treatment because cells throughout the body, including brain cells, need endocytosis for healthy function," said the study's first author, John Cirrito, research instructor in neurology.

"But we are starting to understand the origins of amyloid beta in more detail now, and what we're learning is opening other options we can pursue to seek new treatments for Alzheimer's disease," he said.

The researchers believe the brain cells may be accidentally taking in amyloid precursor protein (APP), which breaks down into amyloid beta.

In that case, they said, a drug that reduces APP intake could help reduce production of amyloid beta.
 

Date created : 2008-04-09

COMMENT(S)